Search Result

Results for "

RAD51

" in MedChemExpress (MCE) Product Catalog:

By Targets:	RAD51 (20) Apoptosis (5) c-Kit (2) c-Met/HGFR (2) CRISPR/Cas9 (1) DNA/RNA Synthesis (3) FLT3 (2) PARP (1) PDGFR (2) Proteasome (1) Reactive Oxygen Species (1) RET (2) Small Interfering RNA (siRNA) (7)
By Research Areas:	Cancer (25)

Inhibitors & Agonists

Antibodies

Targets Recommended: RAD51

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101462

RAD51 Inhibitor B02

5+ Cited Publications

B02
RAD51 Apoptosis Cancer

RAD51 Inhibitor B02 (B02) is an inhibitor of human RAD51 with an IC₅₀ of 27.4 μM.

RAD51 Inhibitor B02 5+ Cited Publications B02	RAD51 Apoptosis	Cancer
RAD51 Inhibitor B02 (B02) is an inhibitor of human *RAD51* with an IC₅₀ of 27.4 μM.

HY-143736

RAD51-IN-5	RAD51	Cancer
RAD51-IN-5 is a potent inhibitor of *RAD51. RAD51* is a eukaryote gene. RAD51-IN-5 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 3) .

HY-RS11603

RAD51 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAD51 Human Pre-designed siRNA Set A contains three designed siRNAs for RAD51 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAD51 Human Pre-designed siRNA Set A RAD51 Human Pre-designed siRNA Set A

HY-RS11604

Rad51 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Rad51 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rad51 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rad51 Mouse Pre-designed siRNA Set A Rad51 Mouse Pre-designed siRNA Set A

HY-RS11605

Rad51 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Rad51 Rat Pre-designed siRNA Set A contains three designed siRNAs for Rad51 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Rad51 Rat Pre-designed siRNA Set A Rad51 Rat Pre-designed siRNA Set A

HY-143737

RAD51-IN-6	RAD51	Cancer
RAD51-IN-6 is a potent inhibitor of *RAD51. RAD51* is a eukaryote gene. RAD51-IN-6 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 23) .

HY-143741

RAD51-IN-7	RAD51	Cancer
RAD51-IN-7 is a potent inhibitor of *RAD51. RAD51* is a eukaryote gene. RAD51-IN-7 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 71) .

HY-143735

RAD51-IN-4	RAD51	Cancer
RAD51-IN-4 is a potent inhibitor of *RAD51. RAD51* is a eukaryote gene. RAD51-IN-4 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2019014315A1, compound R12) .

HY-150958

RAD51-IN-8	RAD51	Cancer
RAD51-IN-8, a new RAD51 binder, is a *RAD51-BRCA2* inhibitor that inhibits the RAD51 BRCA2 protein protein interaction. RAD51-IN-8 also is a protein−protein interaction (PPI) inhibitor. RAD51-IN-8 has inhibitory activity for H4A4 with an EC₅₀ value of 19 μM .

HY-122705

RAD51-IN-1

RAD51 Cancer

RAD51-IN-1, a derivative of B02, is a potent inhibitor of RAD51. RAD51-IN-1 can be used for cancer research .
HY-136604

RAD51-IN-3

RAD51 Cancer

RAD51-IN-3 is a Rad51 inhibitor extracted from patent WO2019051465A1, compound Example 66A .
HY-111887

Emzadirib

RAD51-IN-2
RAD51 Cancer

Emzadirib (RAD51-IN-2) is a RAD51 inhibitor extracted from patent WO2019/051465A1 .

RAD51-IN-1	RAD51	Cancer
RAD51-IN-1, a derivative of B02, is a potent inhibitor of *RAD51. RAD51*-IN-1 can be used for cancer research .

RAD51-IN-3	RAD51	Cancer
RAD51-IN-3 is a *Rad51* inhibitor extracted from patent WO2019051465A1, compound Example 66A .

Emzadirib RAD51-IN-2	RAD51	Cancer
Emzadirib (RAD51-IN-2) is a *RAD51* inhibitor extracted from patent WO2019/051465A1 .

HY-RS11607

RAD51B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAD51B Human Pre-designed siRNA Set A contains three designed siRNAs for RAD51B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAD51B Human Pre-designed siRNA Set A RAD51B Human Pre-designed siRNA Set A

HY-RS11608

RAD51C Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAD51C Human Pre-designed siRNA Set A contains three designed siRNAs for RAD51C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAD51C Human Pre-designed siRNA Set A RAD51C Human Pre-designed siRNA Set A

HY-RS11609

RAD51D Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAD51D Human Pre-designed siRNA Set A contains three designed siRNAs for RAD51D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAD51D Human Pre-designed siRNA Set A RAD51D Human Pre-designed siRNA Set A

HY-RS11606

RAD51AP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAD51AP1 Human Pre-designed siRNA Set A contains three designed siRNAs for RAD51AP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAD51AP1 Human Pre-designed siRNA Set A RAD51AP1 Human Pre-designed siRNA Set A

HY-162104

BRCA2-RAD51-IN-1

Others Cancer

BRCA2-RAD51-IN-1 (Compound 46) is a BRCA2-RAD51 inhibitor with an EC₅₀ value of 28 μM. BRCA2-RAD51-IN-1 has antitumor activity .

*BRCA2-RAD51-IN-1*	Others	Cancer
BRCA2-RAD51-IN-1 (Compound 46) is a *BRCA2-RAD51* inhibitor with an EC₅₀ value of 28 μM. BRCA2-RAD51-IN-1 has antitumor activity .

HY-15317

RI-1 4 Publications Verification	RAD51	Cancer
RI-1 is a *RAD51* inhibitor, with IC₅₀s ranging from 5 to 30 μM. RI-1 binds covalently to the surface of RAD51 protein at cysteine 319. RI-1 inactivates RAD51 by directly binding to a protein surface that serves as an interface between protein subunits in RAD51 filaments. RI-1 can disrupt homologous recombination in human cells .

HY-103710

IBR2 3 Publications Verification	RAD51 Apoptosis	Cancer
IBR2 is a potent and specific *RAD51* inhibitor and inhibits *RAD51*-mediated DNA double-strand break repair. IBR2 disrupts *RAD51* multimerization, accelerates proteasome-mediated *RAD51* protein degradation, inhibits cancer cell growth and induces apoptosis .

HY-121693

DIDS	RAD51	Cancer
DIDS is a potent *RAD51* inhibitor. DIDS inhibits the RAD51-mediated homologous pairing and strand-exchange reactions. DIDS inhibits anion exchange and binding to the red blood cell membrane .

HY-126972A

RI(dl)-2 TFA	RAD51	Cancer
RI(dl)-2 TFA is a potent and selective RAD51-mediated D-loop formation inhibitor with an IC₅₀ of 11.1 μM. RI(dl)-2 TFA does not influence RAD51 binding to ssDNA and inhibits homologous recombination (HR) activity in human cells (IC₅₀ of 3.0 μM) .

HY-150147

CAM833	RAD51 Apoptosis	Cancer
CAM833 is a potent orthosteric inhibitor of the interaction between BRCA2 and *RAD51* with a K_d of 366 nM against the ChimRAD51 protein. CAM833 also inhibits RAD51 oligomerization. CAM833 increases the progression of G2/M-arrested cells into apoptosis .

HY-19793

RS-1

1 Publications Verification

RAD51 CRISPR/Cas9 Cancer

RS-1 is a RAD51 activator, and also increases CRISPR/Cas9-mediated knock-in efficiencies.

RS-1 1 Publications Verification	RAD51 CRISPR/Cas9	Cancer
RS-1 is a *RAD51* activator, and also increases CRISPR/Cas9-mediated knock-in efficiencies.

HY-148183

Homologous recombination-IN-1	RAD51	Cancer
Homologous recombination-IN-1 is a novel RAD51-BRCA2 protein-protein interaction inhibitor (EC₅₀=19 μM). Homologous recombination-IN-1 can interfere with homologous recombination .

HY-16904

RI-2 1 Publications Verification	RAD51	Cancer
RI-2 is a reversible *RAD51* inhibitor, with an IC₅₀ of 44.17 μM, and specifically inhibits homologous recombination repair in human cells.

HY-126020

Bractoppin 2 Publications Verification	DNA/RNA Synthesis RAD51	Cancer
Bractoppin is a potent and selective agent-like inhibitor of phosphopeptide recognition by the human BRCA1 tandem(t) BRCT domain (binding IC₅₀: 74 nM). Bractoppin diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51. Bractoppin preferentially inhibits BRCA1 tBRCT-dependent steps in the DNA damage response .

HY-157212

PARP-1/Proteasome-IN-1	Apoptosis PARP Proteasome	Cancer
PARP-1/Proteasome-IN-1 (compound 42i) is a dual PARP-1 and proteasome inhibitor with significant inhibitory effects on breast cancer. PARP-1/Proteasome-IN-1 can downregulate the expression of BRCA1 and RAD51 to inhibit homologous recombination repair function and induce apoptosis .

HY-10206

Amuvatinib 5+ Cited Publications MP470; HPK 56	c-Kit PDGFR RAD51 FLT3 c-Met/HGFR RET Apoptosis	Cancer
Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein *RAD51*, thereby disrupting DNA damage repair . Antineoplastic activity .

HY-10206A

Amuvatinib hydrochloride MP470 hydrochloride; HPK 56 hydrochloride	c-Kit PDGFR RAD51 FLT3 c-Met/HGFR RET	Cancer
Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein *RAD51*, thereby disrupting DNA damage repair . Antineoplastic activity .

HY-146194

NHEJ inhibitor-1	Reactive Oxygen Species	Cancer
NHEJ inhibitor-1 (Compound C2) is a trifunctional Pt(II) complex, alleviates the non-homologous end connection (NHEJ)/homologous recombination (HR)-related double strand breaks (DSBs) repairs to evade Cisplatin-resistance in non-small cell lung cancer (NSCLC). NHEJ inhibitor-1 inhibits the damage repair proteins Ku70 and Rad51 to make tumors re-sensitive to Cisplatin。NHEJ inhibitor-1 also induces ROS generation and MMP deduction .

HY-124691

D-I03 2 Publications Verification	DNA/RNA Synthesis	Cancer
D-I03 is a selective *RAD52* inhibitor with a K_d of 25.8 µM. D-I03 specifically inhibits *RAD52*-dependent single-strand annealing (SSA) and D-loop formation with IC₅₀s of 5 µM and 8 µM, respectively. D-I03 suppresses growth of BRCA1- and BRCA2-deficient cells and inhibits formation of damage-induced *RAD52* foci, but does not effect on RAD51 foci induced by Cisplatin .

HY-110185

NSC 617145	DNA/RNA Synthesis	Cancer
NSC 617145 is a selective werner syndrome helicase (WRN) helicase inhibitor with an IC₅₀ value of 230 nM. NSC 617145 inhibits WRN ATPase, and induces double-strand breaks (DSB) and chromosomal abnormalities. NSC 617145 shows selective for WRN over BLM, FANCJ, ChlR1, RecQ, and UvrD helicases .

Rad51 Antibody	WB, ICC/IF, IHC-P, FC, IP	Human, Mouse, Rat
Rad51 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 37 kDa, targeting to Rad51. It can be used for WB,ICC/IF,IHC-P,FC,IP assays with tag free, in the background of Human, Mouse, Rat.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: